Erbitux (cetuximab) / Eli Lilly, EMD Serono 
Welcome,         Profile    Billing    Logout  
 245 Diseases   372 Trials   372 Trials   11200 News 


«12...345678910111213...141142»
  • ||||||||||  divarasib (RG6330) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Divarasib Plus Cetuximab Is Safe and Has Efficacy in Colorectal Cancer. (Pubmed Central) -  Dec 21, 2023   
    This study provides a rich resource for investigating the mechanisms and indicators of chemoradiation and targeted therapy in CRC. Divarasib plus cetuximab is well tolerated in patients with KRAS G12C-positive colorectal cancer.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion, Trial completion date:  PD 0332991 and Cetuximab in Patients With Incurable SCCHN (clinicaltrials.gov) -  Dec 21, 2023   
    P1/2,  N=96, Completed, 
    Divarasib plus cetuximab is well tolerated in patients with KRAS G12C-positive colorectal cancer. Active, not recruiting --> Completed | Trial completion date: Oct 2024 --> Nov 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion, Trial completion date, Surgery, Metastases:  Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer (clinicaltrials.gov) -  Dec 19, 2023   
    P=N/A,  N=15, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> May 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Journal, IO biomarker, Metastases:  Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer. (Pubmed Central) -  Dec 17, 2023   
    Finally, we look towards the future and describe contexts in which these agents are currently being investigated clinically with a focus on combinations with MAPK-targeted therapies and immunotherapy. Overall, this review provides historical context, current clinical usage, and future directions for anti-EGFR antibodies in advanced colorectal cancer.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer. (Pubmed Central) -  Dec 17, 2023   
    There is also evidence that EPHA2 plays a key role in the development of resistance to the endothelial growth factor receptor (EGFR) monoclonal antibody Cetuximab used clinically in CRC...In this concept paper, general strategies for EPHA2 inhibition with molecules of low molecular weight (small molecules) are described. Furthermore, available examples of inhibiting EPHA2 in CRC using small molecules are summarized, highlighting the potential of this approach.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Journal, Real-world evidence, Real-world, Metastases:  Atypical (non-V600E) BRAF mutations in metastatic colorectal cancer in population and real-world cohorts. (Pubmed Central) -  Dec 17, 2023   
    Nine patients with aBRAFmt received cetuximab/panitumumab without response...OS for patients with aBRAFmt tumours was slightly better than for BRAF-V600Emt, but worse than for RASmt and RAS&BRAFwt. aBRAFmt should not be a contraindication for metastasectomy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, IO biomarker:  Synergistic Approach of Antibody-Photosensitizer Conjugate Independent of KRAS-mutation and its Downstream Blockade Pathway in Colorectal Cancer. (Pubmed Central) -  Dec 17, 2023   
    To specifically target Kirsten rat sarcoma 2 viral oncogene homolog (KRAS)-mutated cancer cells, an antibody antiepidermal growth factor receptor (EGFR), cetuximab, with a poloxamer linker coupled with the photosensitizer chlorin e6 through click chemistry (cetuximab-maleimide-poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide)-chlorine e6 conjugate, CMPXC) is synthesized...Furthermore, CMPXC treatment led to a 2.24- and 1.75-fold increase in dendritic and priming cytotoxic T cells, respectively, highlighting the immune-activating potential of this approach. Our findings suggest that the APC platform addresses the challenges associated with ADC development and EGFR-targeted therapy, including the synergistic advantages of antibody-mediated immunotherapy and PDT.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Retrospective data, Review, Journal, Checkpoint inhibition:  Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis. (Pubmed Central) -  Dec 9, 2023   
    Combination strategies with targeted drugs or chemotherapy might represent a better therapeutic strategy for these patients. Further studies are awaited to identify resistance mechanisms to ICIs and optimize their efficacy.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Dec 8, 2023   
    P2,  N=43, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Jul 2024 --> Dec 2023 Unknown status --> Completed | Trial completion date: Jan 2021 --> Jul 2023 | Trial primary completion date: Jan 2020 --> Dec 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Imfinzi (durvalumab) / AstraZeneca
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) -  Dec 7, 2023   
    P2,  N=36, Active, not recruiting, 
    Unknown status --> Completed | Trial completion date: Jan 2021 --> Jul 2023 | Trial primary completion date: Jan 2020 --> Dec 2022 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Analysis of immune-related genes (IRGs) and their potential role in sexual dimorphism in patients (pts) with metastatic colorectal cancer (mCRC). (Level 1, West Hall; Poster Bd # L10) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_826;    
    Further, the impact on outcome of 5 selected germline single nucleotide polymorphisms (SNPs) in 3 significant IRGs, SCG2 (rs600257, rs9283537), CRIP2 rs66717274, and AXIN2 (rs7591, rs2240308), was evaluated in genotyped (OncoArray, Illumina) samples of 451 pts from 2 clinical trials: FIRE-3 (FOLFIRI-bev, N = 107; FOLFIRI-cet, N = 129) and TRIBE (FOLFIRI-bev, N = 215)... Our results highlight important role for SCG2, CRIP2, and AXIN2 as prognostic and predictive biomarkers for first-line treatment in mCRC, with potential targeted agent- and pt
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Genome-wide association study (GWAS) and novel prognostic markers in metastatic colorectal cancer (mCRC). (Level 1, West Hall; Poster Bd # L2) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_818;    
    These results suggest that germline genetic variation in MLPH and TYR may affect mCRC prognosis via a mechanism that involves melanin and possibly the epithelial-mesenchymal transition. Note: Authors Millstein and Lenz contributed equally to this work.
  • ||||||||||  LY3537982 / Eli Lilly
    Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study. (Level 1, West Hall; Poster Bd # F17) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_740;    
    P1/2
    Clinical trial information: NCT04956640. >aEfficacy evaluable pts are those who had at least 1 post-baseline response assessment or had discontinued treatment before the first post-baseline assessment.bDCR = PR+SD.c1 CRC, 2 PANC, and 1 duodenal cancer pt (other GI) have unconfirmed PR, ongoing and pending confirmation.dOther GI includes duodenal cancer (n=3), small intestine (n=2), esophageal cancer, jejunal adenocarcinoma (both n=1).e1 pt with small intestine cancer is not yet evaluable.f8 pts are not yet evaluable.g3 pts have unconfirmed PR, ongoing and pending confirmation.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    Retrospective analysis of the real-world demographics, clinical characteristics, and treatment patterns in metastatic CRC among patients treated with encorafenib in combination with cetuximab in the United States. (Level 1, West Hall; Poster Bd # E6) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_710;    
    Adults ?18 years old with ?1 claim for enco (first claim for enco on/after 4/1/2020) with concurrent cetux, as approved, or with EGFR panitumumab (pani), ?2 ICD-9/10 codes for malignancy of the colon or rectum ?30 days apart in the 1 year before index date, and ?1 day of pharmacy and medical continuous enrollment during the index date were included...Among the enco patients who had a previous treatment computed in claims, FOLFOX +/- bevacizumab (beva) and FOLFIRI + beva were the most common. This study provides current RW demographics, disease characteristics and treatment patterns among BRAF mCRC patients treated with enco in the US.
  • ||||||||||  WU-NK-101 / Wugen
    Phase classification, Trial initiation date, Combination therapy, Metastases:  A Phase 1b Study of WU-NK-101 in Combination With Cetuximab (clinicaltrials.gov) -  Dec 4, 2023   
    P1,  N=30, Not yet recruiting, 
    Initiation date: Sep 2023 --> Jan 2024 Phase classification: P1b --> P1 | Initiation date: Nov 2023 --> Jun 2024